Bicara Therapeutics (BCAX) Profit After Tax (2023 - 2026)

Bicara Therapeutics has reported Profit After Tax for 4 years, with the latest figure at -$56.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 52.56% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$157.3 million (down 70.38% YoY), and the FY2025 full-year result was -$138.0 million, down 102.88% from the prior year.
• Profit After Tax for Q1 2026 stood at -$56.2 million, down from -$37.4 million in the prior quarter.
• The five-year high for Profit After Tax was -$12.4 million in Q4 2023, with the low at -$56.2 million in Q1 2026.
• Historically, Profit After Tax has averaged -$27.0 million across 4 years, with a median of -$22.8 million in 2023.
• Annual changes were most pronounced in 2024 — Profit After Tax increased 23.48% — and 2025, when it sank 194.58%.
• Bicara Therapeutics' Profit After Tax stood at -$12.4 million in 2023, then sank by 68.46% to -$21.0 million in 2024, then plunged by 78.39% to -$37.4 million in 2025, then slumped by 50.35% to -$56.2 million in 2026.
• The last three Profit After Tax figures came in at -$56.2 million (Q1 2026), -$37.4 million (Q4 2025), and -$36.3 million (Q3 2025), per Business Quant data.